Lifileucel plus pembrolizumab shows durable responses in first-line advanced melanoma

T-cell engagers in mAPMR/mCRPC prostate cancer

HBI-8000 plus nivolumab significantly improves progression-free survival in advanced melanoma

Neoadjuvant trastuzumab deruxtecan targets HER2-low breast cancer cells to assess tumour response before surgery

Perioperative pembrolizumab fails to significantly improve event-free survival in muscle-invasive bladder cancer

WCLC 2026: Lung cancer research highlights

Isa-VRd shows sustained benefit in transplant-ineligible newly diagnosed multiple myeloma

Subcutaneous tarlatamab shows promising safety and activity in previously treated extensive-stage SCLC

Adagrasib plus cetuximab shows activity but does not improve survival in KRAS G12C-mutated metastatic colorectal cancer

Zolbetuximab plus chemo in CLDN18.2-positive metastatic pancreatic cancer does not improve OS

Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC

ASCO 2026: Updates in bladder cancer